A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension

NCT00631917 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

774

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypertension

Interventions

DRUG: Aliskiren
DRUG: Ramipril
OTHER: Placebo to Ramipril
OTHER: Placebo to Aliskiren

Sponsor

Novartis